Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive biomarker that permits early diagnosis of antibody-mediated rejection (AMR) in kidney transplant recipients with de novo anti-HLA donor ...

More information: Hua Bao et al, Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics, Nature Medicine (2025). DOI: 10.1038/s41591-025-03735-2 ...

Aldevron unveiled Alchemy™ cell-free DNA technology. The technology was designed to support development and preclinical programs, with a future cGMP offering expected to launch in 2025 to ...

Article Title Efficacy of microbial cell-free DNA testing for detecting pathogens in pediatric patients with head and neck infections—An initial study ...

Akifova A, Budde K, Amann K, et al. Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial. Nephrol Dial Transplant.

HAYWARD, Calif.--(BUSINESS WIRE)--Aqtual, Inc., a precision medicine company with a novel active chromatin cell-free DNA (cfDNA ac) platform to develop products for chronic diseases and oncology ...

Scientists manufacture many biotherapeutic products in immortalized cell lines, most commonly HEK293. Residual HEK293 DNA in biotherapeutic candidates can harbor tumorigenic or retroviral sequences ...

Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers t ...

CAP accredited, ISO 13485 certified, and CLIA certified. About Natera Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health.